Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma

Authors

Joanne Jee Yeon Lee, Loma Linda University HealthFollow
Donovan Kearns, Loma Linda University HealthFollow
Medora Rodrigues, Loma Linda University HealthFollow
Blake Babcock, Loma Linda University HealthFollow
Naveenraj L. Solomon MD, Loma Linda University HealthFollow
Maheswari Senthil MD, Loma Linda University HealthFollow
Mark E. Reeves MD, PhD, Loma Linda University HealthFollow
Carlos A. Garberoglio MD, Loma Linda University HealthFollow
Jukes P. Namm MD, Loma Linda University HealthFollow

Class Year

2020

Abstract

Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma.

Recommended Citation

Lee, Joanne Jee Yeon; Kearns, Donovan; Rodrigues, Medora; Babcock, Blake; Solomon, Naveenraj L. MD; Senthil, Maheswari MD; Reeves, Mark E. MD, PhD; Garberoglio, Carlos A. MD; and Namm, Jukes P. MD (2018) "Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma," Loma Linda University Student Journal: Vol. 3: Iss. 1, Article 6.
Available at: https://scholarsrepository.llu.edu/llu-student-journal/vol3/iss1/6